Peripheral nerve neurolymphomatosis: Clinical features, treatment, and outcomes.
all clinical neurophysiology
hematologic
natural history studies
nerve tumour
peripheral neuropathy
Journal
Muscle & nerve
ISSN: 1097-4598
Titre abrégé: Muscle Nerve
Pays: United States
ID NLM: 7803146
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
06
01
2020
revised:
28
07
2020
accepted:
09
08
2020
pubmed:
14
8
2020
medline:
5
1
2021
entrez:
14
8
2020
Statut:
ppublish
Résumé
This series characterises nine patients with neurohistopathologically proven peripheral nerve neurolymphomatosis. A search of the hospital neuropathology database from 2002 to 2019 identified biopsy proven cases. Clinical data, investigation modalities, treatments, and outcomes were collated. Median age at neuropathy onset was 47 y, the neuropathy commonly as the initial lymphoma disease manifestation. Most (8/9) presented with painful asymmetrical sensory disturbance, with additional cranial nerve involvement in three. Neurophysiology typically demonstrated multiple axonal mononeuropathies. Cerebrospinal fluid protein was often raised (6/8). Magnetic resonance imaging suggested peripheral nerve infiltration in 6/9 and positron emission tomography CT in 4/9. Bone marrow biopsy was abnormal in 6/8. Treatment involved systemic or intrathecal chemotherapy and radiotherapy. Median survival was 23 mo. Neurolymphomatosis is a rare but important cause of neuropathy, particularly in those lacking systemic evidence of lymphoma as correct aggressive treatment can prolong survival. Nerve biopsy is essential to classify lymphoma type and rule out alternatives.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
617-625Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Baehring JM, Damek D, Martin EC, et al. Neurolymphomatosis. Neuro Oncol. 2003;5:104-115.
van den Bent MJ, de Bruin HG, Bos GM, et al. Negative sural nerve biopsy in neurolymphomatosis. J Neurol. 1999;246:1159-1163.
Shree R, Goyal MK, Modi M, et al. The diagnostic dilemma of neurolymphomatosis. J Clin Neurol. 2016;12:274-281.
Kamiya-Matsuoka C, Shroff S, Gildersleeve K, Hormozdi B, Manning JT, Woodman KH. Neurolymphomatosis: a case series of clinical manifestations, treatments and outcomes. J Neurol Sci. 2014;343:144-148.
Lin M, Kilanowska J, Taper J, Chu J. Neurolymphomatosis-diagnosis and assessment of treatment response by FDG PET-CT. Hematol Oncol. 2008;26:43-45.
Tomita M, Koike H, Kawagashira Y, et al. Clinicopathological features of neuropathy associated with lymphoma. Brain. 2013;136:2563-2578.
Grisariu S, Avni B, Batchelor TT, et al. Neurolymphomatosis: an international primary CNS lymphoma collaborative group report. Blood. 2010;115:5005-5011.
Briani C, Visentin A, Cavallaro T, et al. Primary neurolymphomatosis as clinical onset of chronic lymphocytic leukemia. Ann Hematol. 2017;96:159-161.
Patel N, Rao VA, Heilman-Espinoza ER, Lai R, Quesada RA, Flint AC. Simple and reliable determination of the modified Rankin scale score in neurosurgical and neurological patients: the mRS-9Q. Neurosurgery. 2012;71:971-975.
Graham RC. Hughes RAC. A modified peripheral neuropathy scale: the overall neuropathy limitations scale. J Neurol Neurosurg Psychiatry. 2006;77:973-976.
Van den Bergh PYK, Hadden RDM, Bouche P, et al. European Federation of Neurological Societies/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripher. Eur J Neurol. 2010;17:356-363.
Poulain S, Boyle EM, Roumier C, et al. MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome. Br J Haematol. 2014;167:506-513.
Park HJ, Shin HY, Kim SH, et al. Partial conduction block as an early nerve conduction finding in Neurolymphomatosis. J Clin Neurol. 2018;14:73-80.
Hamadeh F, MacNamara SP, Aguilera NS, et al. MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma. Mod Pathol. 2014;28:1-11.
Matsue K, Hayama BY, Iwama KI, et al. High frequency of neurolymphomatosis as a relapse disease of intravascular large B-cell lymphoma. Cancer. 2011;117:4512-4521.
Grisariu S, Avni B, Batchelor TT, et al. Neurolymphomatosis: an international primary CNS lymphoma collaborative group report. Blood. 2016;115:5005-5012.
Gan HK, Azad A, Cher L, Mitchell PLR. Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab. Neuro Oncol. 2010;12:212-215.
Correale J, Monteverde DA, Bueri JA, et al. Peripheral nervous system and spinal cord involvement in lymphoma. Acta Neurol Scand. 1991;83:45-51.
Briani C, Visentin A, Cavallaro T, et al. Primary neurolymphomatosis as clinical onset of chronic lymphocytic leukemia. Ann Hematol. 2017;96(1):159-161.
Grisold W, Klimpfinger M, Maehr B, et al. Peripheral nerve involvement in lymphoma: the meninges as the crucial barrier between meningoradicular spread and neurolymphomatosis. J Peripher Nerv Syst. 2007;12:58-60.
Connor AO, McFeely O, Bermingham N, et al. Cerebrospinal fluid (Csf) cytology: factors impacting on diagnostic yield. J Neurol Neurosurg Psychiatry. 2016;87:e1.107.
Vijayan J, Chan YC, Therimadasamy A, et al. Role of combined B-mode and Doppler sonography in evaluating neurolymphomatosis. Neurology. 2015;85:752-755.
Duchesne M, Roussellet O, Maisonobe T, et al. Pathology of nerve biopsy and diagnostic yield of PCR-based Clonality testing in Neurolymphomatosis. J Neuropathol Exp Neurol. 2018;77:769-781.
DeVries AH, Howe BM, Spinner RJ, et al. B-cell peripheral neurolymphomatosis: MRI and 18F-FDG PET/CT imaging characteristics. Skeletal Radiol. 2019;48:1043-1050.
Mcmillan A, Ardeshna KM, Cwynarski K, et al. Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology. Br J Haematol. 2013;163:168-181.
Chaganti S, Illidge T, Barrington S, et al. Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol. 2016;174:43-56.